Elicio Therapeutics, Inc. (ELTX)
(Delayed Data from NSDQ)
$9.20 USD
+0.13 (1.43%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $9.19 -0.01 (-0.11%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ELTX 9.20 +0.13(1.43%)
Will ELTX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ELTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ELTX
Here's Why Elicio Therapeutics (ELTX) Could be Great Choice for a Bottom Fisher
Is Elicio Therapeutics, Inc. (ELTX) Stock Outpacing Its Medical Peers This Year?
ELTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Elicio Therapeutics (ELTX) Upgraded to Buy: Here's What You Should Know
All You Need to Know About Elicio Therapeutics (ELTX) Rating Upgrade to Strong Buy
Other News for ELTX
Elicio Therapeutics GAAP EPS of -$0.66
JonesTrading Sticks to Their Buy Rating for Elicio Therapeutics (ELTX)
Elicio Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate ...
Elicio Therapeutics (ELTX) Advances with Positive Interim Trial Review
Elicio announces positive recommendation by IDMC to continue ELI-002 Phase 2